Fmr LLC Has $859,000 Position in Heron Therapeutics, Inc. (NASDAQ:HRTX)

Fmr LLC grew its position in Heron Therapeutics, Inc. (NASDAQ:HRTX) by 26.2% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 431,906 shares of the biotechnology company’s stock after acquiring an additional 89,601 shares during the period. Fmr LLC owned about 0.28% of Heron Therapeutics worth $859,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of HRTX. nVerses Capital LLC acquired a new position in shares of Heron Therapeutics in the second quarter valued at $27,000. HB Wealth Management LLC bought a new stake in shares of Heron Therapeutics during the 2nd quarter worth about $35,000. Cutter & CO Brokerage Inc. acquired a new position in Heron Therapeutics in the 3rd quarter valued at about $39,000. B. Riley Wealth Advisors Inc. bought a new position in Heron Therapeutics in the 2nd quarter valued at about $41,000. Finally, Sei Investments Co. acquired a new stake in Heron Therapeutics during the second quarter worth approximately $44,000. 80.01% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on HRTX shares. Needham & Company LLC reaffirmed a “buy” rating and issued a $4.00 target price on shares of Heron Therapeutics in a research report on Wednesday, December 4th. StockNews.com upgraded Heron Therapeutics from a “hold” rating to a “buy” rating in a research note on Wednesday, December 11th.

Heron Therapeutics Stock Down 1.8 %

NASDAQ HRTX opened at $1.65 on Wednesday. The firm has a 50-day moving average price of $1.57 and a two-hundred day moving average price of $2.24. Heron Therapeutics, Inc. has a 12-month low of $1.04 and a 12-month high of $3.93. The company has a market capitalization of $250.96 million, a P/E ratio of -9.17 and a beta of 1.67.

Heron Therapeutics (NASDAQ:HRTX) last issued its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported ($0.03) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.03). The company had revenue of $32.81 million during the quarter, compared to the consensus estimate of $36.40 million. During the same quarter last year, the firm posted ($0.17) earnings per share. Equities analysts expect that Heron Therapeutics, Inc. will post -0.13 EPS for the current year.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.